Orally administered saccharide-sequestering nanocomplex to manage carbohydrate metabolism disorders

Excessive carbohydrate intake is linked to the growing prevalence of diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity. α-Glucosidases inhibitor, the only Food and Drug Administration–approved drug for limiting the absorption of polysaccharides and disaccharides, is ineffective for mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xin, Zhang, Huijun, Li, Jiacheng, Tian, Meng, Yang, Juanjuan, Sun, Songxuan, Hu, Qixin, Yang, Liu, Zhang, Shiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011972/
https://www.ncbi.nlm.nih.gov/pubmed/33789906
http://dx.doi.org/10.1126/sciadv.abf7311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011972/
https://www.ncbi.nlm.nih.gov/pubmed/33789906
http://dx.doi.org/10.1126/sciadv.abf7311

Ejemplares similares